Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 4,169 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 4,169 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $3.15, for a total transaction of $13,132.35. Following the completion of the sale, the insider now directly owns 134,921 shares in the company, valued at approximately $425,001.15. This represents a 3.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gina Mazzariello also recently made the following trade(s):

• On Monday, February 3rd, Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $3.49, for a total transaction of $12,836.22.

Amylyx Pharmaceuticals Price Performance

NASDAQ:AMLX opened at $3.20 on Thursday. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $19.95. The company has a market cap of $219.35 million, a P/E ratio of -0.84 and a beta of -0.54. The firm’s fifty day moving average price is $3.63 and its two-hundred day moving average price is $3.82.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of AMLX. abrdn plc grew its stake in shares of Amylyx Pharmaceuticals by 1,567.9% in the third quarter. abrdn plc now owns 1,972,242 shares of the company’s stock valued at $6,390,000 after acquiring an additional 1,853,995 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Amylyx Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after acquiring an additional 5,104 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Amylyx Pharmaceuticals by 41.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 880,745 shares of the company’s stock valued at $2,854,000 after acquiring an additional 258,818 shares in the last quarter. FMR LLC grew its stake in shares of Amylyx Pharmaceuticals by 292.0% in the third quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after acquiring an additional 164,622 shares in the last quarter. Finally, Alpha Wave Global LP acquired a new position in shares of Amylyx Pharmaceuticals in the third quarter valued at about $2,169,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on AMLX shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Baird R W raised shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Robert W. Baird raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.